Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Adimmune's Enterprise Value is NT$8,368 Mil.
Adimmune's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was NT$-242 Mil. Therefore, Adimmune's EV-to-EBIT for today is -34.61.
The historical rank and industry rank for Adimmune's EV-to-EBIT or its related term are showing as below:
TPE:4142'
s EV-to-EBIT Range Over the Past 10 Years
Min: -812.85 Med: -12.14 Max: 626.25
Current: -34.61
During the past 13 years, the highest EV-to-EBIT of Adimmune was 626.25. The lowest was -812.85. And the median was -12.14.
TPE:4142's EV-to-EBIT is ranked worse than 100% of 370
companies
in the Biotechnology industry
Industry Median: 15.025
vs TPE:4142: -34.61
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Adimmune's Enterprise Value for the quarter that ended in Mar. 2026 was NT$8,705 Mil.
Adimmune's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-242 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adimmune EV-to-EBIT Related Terms
Adimmune EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Adimmune's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4142 vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Adimmune's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adimmune EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adimmune's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Adimmune's EV-to-EBIT falls into.
Adimmune's current Enterprise Value is NT$8,368 Mil.
Adimmune's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-242 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adimmune (TPE:4142) has a EV-to-EBIT of -34.61 as of Aug. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Adimmune and its competitors. According to the industry distribution chart, Adimmune ranks #999999 out of 370 companies in the Biotechnology industry.
Is Adimmune's EV-to-EBIT too high?
Adimmune's current EV-to-EBIT is -34.61. Based on the distribution chart, Adimmune ranks #999999 out of 370 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Adimmune has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Adimmune's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Adimmune ranks #999999 out of 370 companies for EV-to-EBIT. This places Adimmune in the lower half of its industry. The industry median EV-to-EBIT is 15.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.03, based on 370 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Adimmune and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adimmune's current EV-to-EBIT is -34.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adimmune stock overvalued right now?
Based on GuruFocus' analysis, Adimmune (TPE:4142) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$20.08, compared to a current price of NT$17.55 — trading 12.6% below its estimated fair value. The current EV-to-EBIT is -34.61. Adimmune's overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Adimmune (TPE:4142), the current EV-to-EBIT is -34.61 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adimmune (TPE:4142) Overvalued in 2026?
Based on GuruFocus' analysis, Adimmune stock appears to be undervalued.
The current stock price of NT$17.55 is trading 12.6% below its estimated GF Value™ of NT$20.08.
GuruFocus considers Adimmune to be Modestly Undervalued.
Key valuation signals for TPE:4142:
EV-to-EBIT: -34.61
GF Value™: NT$20.08 vs. price of NT$17.55 (12.6% below fair value)
No single metric tells the full story. See the TPE:4142 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adimmune Corp is engaged in the research and development, processing, manufacturing, and trading of serum, vaccines, testing reagents, biologicals, and other bacterial fluids, as well as western medicines, animal medicines, chemicals, and feed additives. Its segments are separated by business as Adimmune Corporation, which generates maximum revenue and is engaged in the manufacturing of influenza vaccines with EU GMP and US FDA certificates in Taiwan. Its products include Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, and others, and Enimmune Corporation. The Group's revenue is mainly from the manufacturing and trading of vaccines, modern medicine products and testing reagents, as well as entrusted packing of vaccines.
59GF Score
Get the complete analysis for TPE:4142
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4142 has been successfully added to your 
